Oral administration of glucosylceramide ameliorates inflammatory dry-skin condition in chronic oxazolone-induced irritant contact dermatitis in the mouse ear

Journal of Dermatological Science

Volumn 67, Issue 2, 2012, Pages 101-110

  Yeom, Mijung ^a   Kim, Sung Hun ^a   Lee, Bombi ^a   Han, Jeong Jun ^b   Chung, Guk Hoon ^b   Choi, Hee Don ^c   Lee, Hyejung ^a   Hahm, Dae Hyun ^a  

^a Kyung Hee University   (South Korea)

^b Glonet BU   (South Korea)

^c Korea Food Research Institute   (South Korea)

Author keywords

Aquaporin 3; Chronic contact dermatitis; Glucosylceramide; Inflammation; Skin hydration

Indexed keywords

AQUAPORIN 3; GLUCOSYLCERAMIDE; INTERLEUKIN 1BETA; INTERLEUKIN 6; OXAZOLONE; PREDNISOLONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL INFILTRATION; CONTROLLED STUDY; DEHYDRATION; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG MEGADOSE; DRY SKIN; EAR EDEMA; GENE EXPRESSION; INFLAMMATORY DRY SKIN; IRRITANT DERMATITIS; LEUKOCYTE MIGRATION; LYMPH NODE; MALE; MAST CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCRATCHING; SKIN INFLAMMATION; STRATUM CORNEUM;

ADMINISTRATION, ORAL; ANIMALS; AQUAPORIN 3; DERMATITIS, CONTACT; DERMATITIS, IRRITANT; EAR; GLUCOSYLCERAMIDES; INFLAMMATION; INTERLEUKIN-1BETA; INTERLEUKIN-6; LYMPH NODES; MALE; MICE; MICE, INBRED BALB C; MODELS, BIOLOGICAL; OXAZOLONE; RNA, MESSENGER; SKIN;

EID: 84863882795     PISSN: 09231811     EISSN: 1873569X     Source Type: Journal    
DOI: 10.1016/j.jdermsci.2012.05.009     Document Type: Article

References (48)

1. Bos J.D., Kapsenberg M.L., Smitt J.H. Pathogenesis of atopic eczema. Lancet 1994, 343:1338-1341.
2. Cork M.J. The importance of skin barrier function. J Dermatolog Treat 1997, 8:S7-S13.
3. Elias P.M., Wood L.C., Feingold K.R. Epidermal pathogenesis of inflammatory dermatoses. Am J Contact Dermat 1999, 10:119-126.
4. Goldstein A.M., Abramovits W. Ceramides and the stratum corneum: structure, function, and new methods to promote repair. Int J Dermatol 2003, 42:256-259.
5. Lynde C. Moisturizers for the treatment of inflammatory skin conditions. J Drugs Dermatol 2008, 7:1038-1043.
6. Sampson H.A. Pathogenesis of eczema. Clin Exp Allergy 1990, 20:459-467.
7. Corsini E., Galli C.L. Epidermal cytokines in experimental contact dermatitis. Toxicology 2000, 142:203-211.
8. Uchi H., Terao H., Koga T., Furue M. Cytokines and chemokines in the epidermis. J Dermatol Sci 2000, 24(Suppl. 1):S29-S38.
9. Loden M., Andersson A.C., Lindberg M. Improvement in skin barrier function in patients with atopic dermatitis after treatment with a moisturizing cream (Canoderm). Br J Dermatol 1999, 140:264-267.
10. Proksch E., Holleran W.M., Menon G.K., Elias P.M., Feingold K.R. Barrier function regulates epidermal lipid and DNA synthesis. Br J Dermatol 1993, 128:473-482.
11. Denda M., Wood L.C., Emami S., Calhoun C., Brown B.E., Elias P.M., et al. The epidermal hyperplasia associated with repeated barrier disruption by acetone treatment or tape stripping cannot be attributed to increased water loss. Arch Dermatol Res 1996, 288:230-238.
12. Lipozencic J., Wolf R. Atopic dermatitis: an update and review of the literature. Dermatol Clin 2007, 25:605-612.
13. Hara-Chikuma M., Verkman A.S. Physiological roles of glycerol-transporting aquaporins: the aquaglyceroporins. Cell Mol Life Sci 2006, 63:1386-1392.
14. Stahle-Backdahl M. Stratum corneum hydration in patients undergoing maintenance hemodialysis. Acta Derm Venereol 1988, 68:531-534.
15. Boury-Jamot M., Daraspe J., Bonte F., Perrier E., Schnebert S., Dumas M., et al. Skin aquaporins: function in hydration, wound healing, and skin epidermis homeostasis. Handb Exp Pharmacol 2009, 205-217.
16. Verkman A.S., Mitra A.K. Structure and function of aquaporin water channels. Am J Physiol Renal Physiol 2000, 278:F13-F28.
17. Rojek A., Praetorius J., Frokiaer J., Nielsen S., Fenton R.A. A current view of the mammalian aquaglyceroporins. Annu Rev Physiol 2008, 70:301-327.
18. Sougrat R., Morand M., Gondran C., Barre P., Gobin R., Bonte F., et al. Functional expression of AQP3 in human skin epidermis and reconstructed epidermis. J Invest Dermatol 2002, 118:678-685.
19. Ma T., Hara M., Sougrat R., Verbavatz J.M., Verkman A.S. Impaired stratum corneum hydration in mice lacking epidermal water channel aquaporin-3. J Biol Chem 2002, 277:17147-17153.
20. Hara M., Ma T., Verkman A.S. Selectively reduced glycerol in skin of aquaporin-3-deficient mice may account for impaired skin hydration, elasticity, and barrier recovery. J Biol Chem 2002, 277:46616-46621.
21. Gehring W., Wenz J., Gloor M. Influence of topically applied ceramide/phospholipid mixture on the barrier function of intact skin, atopic skin and experimentally induced barrier damage. Int J Cosmet Sci 1997, 19:143-156.
22. Sugawara T., Miyazawa T. Separation and determination of glycolipids from edible plant sources by high-performance liquid chromatography and evaporative light-scattering detection. Lipids 1999, 34:1231-1237.
23. Tsuji K., Mitsutake S., Ishikawa J., Takagi Y., Akiyama M., Shimizu H., et al. Dietary glucosylceramide improves skin barrier function in hairless mice. J Dermatol Sci 2006, 44:101-107.
24. Fukunaga K., Yoshida M., Nakajima F., Uematsu R., Hara M., Inoue S., et al. Design, synthesis, and evaluation of beta-galactosylceramide mimics promoting beta-glucocerebrosidase activity in keratinocytes. Bioorg Med Chem Lett 2003, 13:813-815.
25. Uchiyama T., Nakano Y., Ueda O., Mori H., Nakashima M., Noda A., et al. Oral intake of glucosylceramide improves relatively higher level of transepidermal water loss in mice and healthy human subjects. J Health Sci 2008, 54:559-566.
26. Shin Y.W., Bae E.A., Kim S.S., Lee Y.C., Kim D.H. Effect of ginsenoside Rb1 and compound K in chronic oxazolone-induced mouse dermatitis. Int Immunopharmacol 2005, 5:1183-1191.
27. Kupper T.S., Min K., Sehgal P., Mizutani H., Birchall N., Ray A., et al. Production of IL-6 by keratinocytes. Implications for epidermal inflammation and immunity. Ann N Y Acad Sci 1989, 557:454-464. [discussion 464-5].
28. Kupper T.S., Groves R.W. The interleukin-1 axis and cutaneous inflammation. J Invest Dermatol 1995, 105:62S-66S.
29. Man M.Q., Hatano Y., Lee S.H., Man M., Chang S., Feingold K.R., et al. Characterization of a hapten-induced, murine model with multiple features of atopic dermatitis: structural, immunologic, and biochemical changes following single versus multiple oxazolone challenges. J Invest Dermatol 2008, 128:79-86.
30. Asai S., Miyachi H. Evaluation of skin-moisturizing effects of oral or percutaneous use of plant ceramides. Rinsho Byori 2007, 55:209-215.
31. Kimata H. Improvement of atopic dermatitis and reduction of skin allergic responses by oral intake of konjac ceramide. Pediatr Dermatol 2006, 23:386-389.
32. Miyanishi K., Shiono N., Shirai H., Dombo M., Kimata H. Reduction of transepidermal water loss by oral intake of glucosylceramides in patients with atopic eczema. Allergy 2005, 60:1454-1455.
33. Proksch E., Brasch J. Influence of epidermal permeability barrier disruption and Langerhans' cell density on allergic contact dermatitis. Acta Derm Venereol 1997, 77:102-104.
34. Nishijima T., Tokura Y., Imokawa G., Seo N., Furukawa F., Takigawa M. Altered permeability and disordered cutaneous immunoregulatory function in mice with acute barrier disruption. J Invest Dermatol 1997, 109:175-182.
35. Murphy J.E., Robert C., Kupper T.S. Interleukin-1 and cutaneous inflammation: a crucial link between innate and acquired immunity. J Invest Dermatol 2000, 114:602-608.
36. Pastore S., Mascia F., Girolomoni G. The contribution of keratinocytes to the pathogenesis of atopic dermatitis. Eur J Dermatol 2006, 16:125-131.
37. Kitajima T., Ariizumi K., Mohamadazadeh M., Edelbaum D., Bergstresser P.R., Takashima A. T cell-dependent secretion of IL-1 beta by a dendritic cell line (XS52) derived from murine epidermis. J Immunol 1995, 155:3794-3800.
38. Lee C.E., Neuland M.E., Teaford H.G., Villacis B.F., Dixon P.S., Valtier S., et al. Interleukin-6 is released in the cutaneous response to allergen challenge in atopic individuals. J Allergy Clin Immunol 1992, 89:1010-1020.
39. Funding A.T., Johansen C., Gaestel M., Bibby B.M., Lilleholt L.L., Kragballe K., et al. Reduced oxazolone-induced skin inflammation in MAPKAP kinase 2 knockout mice. J Invest Dermatol 2009, 129:891-898.
40. Hankins J.L., Fox T.E., Barth B.M., Unrath K.A., Kester M. Exogenous ceramide-1-phosphate reduces lipopolysaccharide (LPS)-mediated cytokine expression. J Biol Chem 2011, 286:44357-44366.
41. Ueda O., Hasegawa M., Kitamura S. Distribution in skin of ceramide after oral administration to rats. Drug Metab Pharmacokinet 2009, 24:180-184.
42. Nilsson A. Metabolism of cerebroside in the intestinal tract of the rat. Biochim Biophys Acta 1969, 187:113-121.
43. Ono J., Kinoshita M., Aida K., Tamura M., Ohnishi M. Effects of dietary glucosylceramide on dermatitis in atopic dermatitis model mice. Eur J Lipid Sci Technol 2010, 112:708-711.
44. Sugawara T., Tsuduki T., Yano S., Hirose M., Duan J., Aida K., et al. Intestinal absorption of dietary maize glucosylceramide in lymphatic duct cannulated rats. J Lipid Res 2010, 51:1761-1769.
45. Olsson M., Broberg A., Jernas M., Carlsson L., Rudemo M., Suurkula M., et al. Increased expression of aquaporin 3 in atopic eczema. Allergy 2006, 61:1132-1137.
46. Bellemere G., Von Stetten O., Oddos T. Retinoic acid increases aquaporin 3 expression in normal human skin. J Invest Dermatol 2008, 128:542-548.
47. Ashwell J.D., Lu F.W., Vacchio M.S. Glucocorticoids in T cell development and function. Annu Rev Immunol 2000, 18:309-345.
48. Fisher D.A. Adverse effects of topical corticosteroid use. West J Med 1995, 162:123-126.